Document Detail

Sorafenib in combination with transarterial chemoembolization improves survival of unresectable hepatocellular carcinoma: A propensity-score matching study.
MedLine Citation:
PMID:  23324079     Owner:  NLM     Status:  Publisher    
OBJECTIVE: This prospective non-randomized controlled trial was aimed to compare the efficacy of sorafenib in combination with transarterial chemoembolization (TACE) versus TACE alone for treatment of patients with unresectable intermediate/advanced stage hepatocellular carcinoma (HCC). METHODS: A total of 304 patients were enrolled and all treated with TACE, 82 of the patients received concurrent sorafenib (400 mg orally twice daily initiated within 7 days after TACE), and these patients were matched with 164 patients who received TACE alone at a 1:2 ratio using propensity-score matching to minimize selection bias. The response to treatment, time-to-progression (TTP), overall survival (OS) as well as adverse effects were compared between the two groups. RESULTS: During a median follow-up period of 21.4 weeks (range 0.5-103 weeks), the addition of sorafenib improved TTP from 4.3 months to 6.3 months (hazard ratio [HR] 0.60, 95% CI 0.422-0.853, P = 0.004) and prolonged median survival time from 5.1 months to 7.5 months (HR 0.61, 95% CI 0.423-0.884, P = 0.009). Significant prognostic factors for OS by multivariate analyses included the use of sorafenib, BCLC stage, metastasis/vascular invasion, and liver function. CONCLUSIONS: The combined use of sorafenib and TACE was generally well-tolerated and significantly improved the overall survival, TTP, as compared to TACE alone. Further studies are warranted to confirm the safety and efficacy of this combination.
Wei Bai; Yong Ji Wang; Yan Zhao; Xing Shun Qi; Zhan Xin Yin; Chuang Ye He; Rui Jun Li; Kai Chun Wu; Jie Lai Xia; Dai Ming Fan; Guo Hong Han
Related Documents :
18704969 - Cancer of the external auditory canal and middle ear in denmark from 1992 to 2001.
24653929 - Prognostic value of metabolic tumor volume measured by 18f-fdg pet/ct in esophageal can...
21573659 - Recombinant interleukin-2 and interferon-alpha-2a in pretreated advanced soft-tissue sa...
23699599 - Outcomes of patients with poems syndrome treated initially with radiation.
23904849 - A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetux...
25093849 - Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management o...
15743689 - Overexpression of cyclin d1 and interaction between p27kip1 and tumour thickness predic...
12218569 - Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potent...
20972169 - Ponm08 late recurrent thymoma: a case series.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-17
Journal Detail:
Title:  Journal of digestive diseases     Volume:  -     ISSN:  1751-2980     ISO Abbreviation:  J Dig Dis     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101302699     Medline TA:  J Dig Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2013 The Authors. Journal of Digestive Diseases © 2013 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.
Department of Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi Province, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of the Closure Type on the Evolution of the Physical-Chemical and Sensory Characteristics of ...
Next Document:  JContextExplorer: a tree-based approach to facilitate cross-species genomic context comparison.